ACTIVE INGREDIENT: Losartan Potassium
STRENGTH, PACK SIZE & GMS CODES:
50 mg Film-Coated Tablets x 28 ~ 31912
100 mg Film-Coated Tablets x 28 ~ 31913
Lotanos is indicated for the treatment for hypertension.
Reduction in the Risk of Cardiovascular Morbidity in Hypertensive Patients with Left Ventricular Hypertrophy:
Lotanos is indicated to reduce the risk of cardiovascular morbidity as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.
Lotanos is indicated for the treatment of heart failure when treatment with an ACE inhibitor is no longer considered appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Lotanos is not recommended.
Renal Protection in Type 2 Diabetic patients with Proteinuria:
Lotanos is inidicated to delay the progression of renal disease as measured by a reduction in the composite endpoints of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.